Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer: Final findings from the CONTROL trial

Chan, A.Ruiz Borrego, M.Marx, G.Brufsky, A.Chien, A. J.Thirlwell, M. P.Trudeau, M. E.Bose, R.Saenz, J. A. GarciaEgle, D.Pistilli, B.Wassermann, J.Cheong, K. A.Semsek, D.Singer, C. F.Diprimeo, D.Foruzan, N.McCulloch, L. M.Barcenas, C. H.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21900enEffect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancer: Final findings from the CONTROL trialconference outputopen access10.1016/j.annonc.2022.03.0891569-8041http://www.annalsofoncology.org/article/S0923753422004689/pdf792494100075